Breast- Invasive breast cancer of no special type (NST) with strong TACSTD2 immunostaining of tumor cells.

Breast- Invasive lobular breast cancer with weak to moderate TACSTD2 immunostaining of tumor cells. Note: TACSTD2 staining is more intense in a normal breast gland.

Colon- Colorectal adenocarcinoma with a weak to moderate TACSTD2 immunostaining in few tumor cells.

Esophagus- Adenocarcinoma with strong TACSTD2 immunostaining of tumor cells.

Esophagus- Squamous cell carcinoma showing a strong, predominantly membranous TACSTD2 tumor cell positivity.

Kidney- Chromophobe renal cell carcinoma exhibiting a strong membranous TACSTD2 staining of tumor cells.

Kidney- Intense, predominantly membranous TACSTD2 positivity of tumor cells in a papillary renal cell carcinoma.

Kidney- TACSTD2 negative clear cell renal cell carcinoma.

Liver- TACSTD2 negative hepatocellularcellular carcinoma.

Lung- Adenocarcinoma with strong membranous TACSTD2 staining of tumor cells.

Lung- Malignant mesothelioma with moderate membranous TACSTD2 immunostaining in a small fraction of tumor cells.

Lung- Squamous cell carcinoma with strong TACSTD2 immunostaining of tumor cells.

Lung- TACSTD2 negative malignant mesothelioma (epitheloid).

Ovary- Endometroid carcinoma with strong TACSTD2 positivity in 70% of tumor cells.

Ovary- Serous high-grade carcinoma with strong TACSTD2 immunostaining of >90% of tumor cells. A few intermingled tumor cells show much weaker positivity.

Ovary- Serous high-grade carcinoma with strong, predominantly membranous TACSTD2 immunostaining of tumor cells.

Pancreas- TACSTD2 negative neuroendocrine tumor.

Prostate- Adenocarcinoma (Gleason 3+3=6) with strong TACSTD2 immunostaining of tumor cells.

Salivary gland- Warthin tumor with intense predominantly membranous TACSTD2 staining of tumor cells.

Stomach- Gastric adenocarcinoma (diffuse type) with weak to moderate TACSTD2 immunostaining of most tumor cells.

Stomach- Gastric adenocarcinoma with weak to moderate membranous TACSTD2 immunostaining of a small fraction of tumor cells.

Stomach- TACSTD2 negative gastrointestinal stromal tumor (GIST).

Testis- TACSTD2 negative Leydig cell tumor.

Testis- TACSTD2 negative seminoma.

Thyroid- Papillary cancer with strong TACSTD2 positivity of tumor cells.

Thyroid- TACSTD2 negative medullary carcinoma.

Urinary bladder- Muscle-invasive urothelial carcinoma showing a strong TACSTD2 positivity of tumor cells.

Vulva- Squamous cell carcinoma showing strong TACSTD2 immunostaining.